Skip to content

Efficacy of silver zinc sulfadiazine cream containing silk sericin for the treatment of burn wounds

Efficacy of silver zinc sulfadiazine cream containing silk sericin for the treatment of burn wounds: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN79764413
Enrollment
16
Registered
2012-05-28
Start date
2010-09-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second degree burn wounds Injury, Occupational Diseases, Poisoning Burn of second degree, body region unspecified

Interventions

After eligibility was established, an initial evaluation was performed on each patient that included recording subject demographics, medical and social history, and a baseline assessment of the burn i
the physician investigators and other medical personnel were blinded to the type of treatment from the first day of admission until the wounds were completely healed. All patients were treated with fl

Sponsors

National Research Council (Thailand)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 15-60 years of age 2. Second degree burn wounds covering no less than 15% of the total body surface area (TBSA) with no wound infection 3. Patients were to stay at the hospital until the wounds were completely healed

Exclusion criteria

Exclusion criteria: 1. Patients with history of allergy to sulfonamides, sericin, or any of the other ingredients in the formulation 2. Patients who had active diabetes mellitus, chronic obstructive pulmonary disease, psychological problems, dementia, malnutrition or immunodeficiency 3. Patients who experienced abnormal liver or renal function tests prior to enrollment 4. Patients with cancer or receiving chemotherapy and those who were pregnant or breastfeeding 5. Patients who show no response to the treatment, were not willing to continue with the study, or when the physician opined that treatment was no longer needed

Design outcomes

Primary

MeasureTime frame
The wound size was measured using Visitrak Digital and the healing percentage of the wound was calculated. The length of time to heal was also recorded.

Secondary

MeasureTime frame
1. Adverse drug reactions were assessed using Naranjo?s algorithm 2. Pain was assessed in all patients every 7 days using the visual analog scale 30 min after a dressing change 3. Burn health status was also evaluated using Burn-Specific Health Scale-Brief (BSHS-B)

Countries

Thailand

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026